Focused On-demand Library for Polyadenylate-binding protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q86U42

UPID:

PABP2_HUMAN

Alternative names:

Nuclear poly(A)-binding protein 1; Poly(A)-binding protein II; Polyadenylate-binding nuclear protein 1

Alternative UPACC:

Q86U42; D3DS49; O43484

Background:

Polyadenylate-binding protein 2, also known as Nuclear poly(A)-binding protein 1, plays a crucial role in mRNA processing. It is involved in the 3'-end formation of mRNA precursors by adding a poly(A) tail, which is essential for mRNA stability and translation. This protein also participates in mRNA metabolism, including nucleocytoplasmic trafficking and nonsense-mediated decay, and cooperates with SKIP to activate muscle-specific genes.

Therapeutic significance:

Polyadenylate-binding protein 2 is linked to Oculopharyngeal muscular dystrophy, a disease characterized by eyelid ptosis and dysphagia. Understanding the role of this protein could open doors to potential therapeutic strategies for treating this form of myopathy.